Fig. 1.
Fig. 1. Overall and PFS of 59 patients with relapsed or refractory B-cell lymphoma who received dosimetric and/or therapeutic doses of iodine 131I tositumomab.

Overall and PFS of 59 patients with relapsed or refractory B-cell lymphoma who received dosimetric and/or therapeutic doses of iodine 131I tositumomab.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal